Keratinocyte growth factor (KGF) regulates estrogen receptor-α (ER-α) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3195-3205

  Chang, Hsiang Lin ^a   Sugimoto, Yasuro ^a   Liu, Suling ^a   Wang, Li Shu ^a   Huang, Yi Wen ^a   Ye, Weiping ^a   Lin, Young C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Bcl 2 family; Breast cancer; ER ; Estrogen; KGF; PI3 Akt; Tamoxifen

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 HYDROXYTAMOXIFEN; CASPASE 9; ESTROGEN RECEPTOR ALPHA; GENOMIC DNA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL X; RECOMBINANT KERATINOCYTE GROWTH FACTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL KILLING; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; FIBROBLAST GROWTH FACTOR 7; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 68549136607     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Henderson BE, Ross RK, Pike MC and Casagrande JT: Endogenous hormones as a major factor in human cancer. Cancer Res 42: 3232-3239, 1982.
2. Clemons M and Goss P: Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285, 2001.
3. Kuiper GG and Brinkmann AO: Steroid hormone receptor phosphorylation: is there a physiological role? Mol Cell Endocrinol 100: 103-107, 1994.
4. McKenna NJ, Nawaz Z, Tsai SY, Tsai MJ and O'Malley BW: Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc Natl Acad Sci USA 95: 11697-11702, 1998. (Pubitemid 28460477)
5. Love RR: Tamoxifen therapy in primary breast cancer: biology, efficacy, and side-effects. J Clin Oncol 7: 803-815, 1989. (Pubitemid 19145604)
6. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998. (Pubitemid 28439961)
7. Marshall E: Tamoxifen. A 'big deal' but a complex hand to play. Science 280: 196, 1998.
8. Perry RR, Kang Y and Greaves B: Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 2: 238-245, 1995.
9. Thornberry NA and Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998.
10. Mandlekar S, Yu R, Tan TH and Kong AN: Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60: 5995-6000, 2000. (Pubitemid 30839629)
11. Peto R, Boreham J, Clarke M, Davies C and Beral V: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355: 1822, 2000.
12. Martin MB and Stoica A: Insulin-like growth factor-I and estrogen interactions in breast cancer. J Nutr 132: 3799S-3801S, 2002.
13. Stoica GE, Franke TF, Wellstein A, Morgan E, Czubayko F, List HJ, Reiter R, Martin MB and Stoica A: Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene 22: 2073-2087, 2003. (Pubitemid 36539558)
14. Wong CW, McNally C, Nickbarg E, Komm BS and Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 99: 14783-14788, 2002. (Pubitemid 35334561)
15. Nicholson RI, McClelland RA, Robertson JF and Gee JM: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6: 373-387, 1999.
16. Lee AV, Cui X and Oesterreich S: Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 7: 4429s-4435s; discussion 4411s-4412s, 2001. (Pubitemid 34031592)
17. Razandi M, Pedram A, Park ST and Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278: 2701-2712, 2003. (Pubitemid 36801351)
18. Rubin JS, Bottaro DP, Chedid M, Miki T, Ron D, Cheon G, Taylor WG, Fortney E, Sakata H, Finch PW and LaRochelle WL: Keratinocyte growth factor. Cell Biol Int 79: 399-411, 1995.
19. Rubin JS, Bottaro DP, Chedid M, Miki T, Ron D, Cunha GR and Finch PW: Keratinocyte growth factor as a cytokine that mediates mesenchymal-epithelial interaction. EXS 74: 191-214, 1995.
20. Zhang Y, Sugimoto Y, Kulp SK, Farrar WB, Brueggemeier RW and Lin YC: Estrogen-induced keratinocyte growth factor mRNA expression in normal and cancerous human breast cells. Oncol Rep 5: 577-583, 1998. (Pubitemid 28189307)
21. Imagawa W, Cunha GR, Young P and Nandi S: Keratinocyte growth factor and acidic fibroblast growth factor are mitogens for primary cultures of mammary epithelium. Biochem Biophys Res Commun 204: 1165-1169, 1994. (Pubitemid 24367174)
22. Pekonen F, Nyman T and Rutanen EM: Differential expression of keratinocyte growth factor and its receptor in the human uterus. Mol Cell Endocrinol 95: 43-49, 1993. (Pubitemid 23267194)
23. Ulich TR, Yi ES, Cardiff R, Yin S, Bikhazi N, Biltz R, Morris CF and Pierce GF: Keratinocyte growth factor is a growth factor for mammary epithelium in vivo. The mammary epithelium of lactating rats is resistant to the proliferative action of keratinocyte growth factor. Am J Pathol 144: 862-868, 1994. (Pubitemid 24160626)
24. Zang XP, Siwak DR, Nguyen TX, Tari AM and Pento JT: KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2. Clin Exp Metastasis 27: 437-443, 2004.
25. Nguyen TN, Zang XP and Pento JT: Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res 46: 179-183, 2002.
26. Zang XP, Lerner MR, Dunn ST, Brackett DJ and Pento JT: Antisense KGFR oligonucleotide inhibition of KGF-induced motility in breast cancer cells. Anticancer Res 23: 4913-4919, 2003.
27. Itoh N and Ornitz DM: Evolution of the Fgf and Fgfr gene families. Trends Genet 20: 563-569, 2004. (Pubitemid 39314564)
28. Orr-Urtreger A, Bedford MT, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D and Lonai P: Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158: 475-486, 1993. (Pubitemid 23243904)
29. LaRochelle WJ, Dirsch OR, Finch PW, Cheon HG, May M, Marchese C, Pierce JH and Aaronson SA: Specific receptor detection by a functional keratinocyte growth factor-immunoglobulin chimera. J Cell Biol 129: 357-366, 1995.
30. Bao S, Wang Y, Sweeney P, Chaudhuri A, Doseff AI, Marsh CB and Knoell DL: Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 288: L36-42, 2005. (Pubitemid 40023884)
31. Liang Q, Mohan RR, Chen L and Wilson SE: Signaling by HGF and KGF in corneal epithelial cells: Ras/MAP kinase and Jak-STAT pathways. Invest Ophthalmol Vis Sci 39: 1329-1338, 1998. (Pubitemid 28307357)
32. Portnoy J, Curran-Everett D and Mason RJ: Keratinocyte growth factor stimulates alveolar type II cell proliferation through the extracellular signal-regulated kinase and phosphatidylinositol 3-OH kinase pathways. Am J Respir Cell Mol Biol 30: 901-907, 2004. (Pubitemid 38736916)
33. Sharma GD, He J and Bazan HE: p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J Biol Chem 278: 21989-21997, 2003. (Pubitemid 36792607)
34. Taniguchi F, Harada T, Sakamoto Y, Yamauchi N, Yoshida S, Iwabe T and Terakawa N: Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab 88: 773-780, 2003. (Pubitemid 36207821)
35. Song G, Ouyang G and Bao S: The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
36. Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, Haga T and Kikkawa U: Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 216: 526-534, 1995.
37. Klippel A, Reinhard C, Kavanaugh WM, Apell G, Escobedo MA and Williams LT: Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol 16: 4117-4127, 1996. (Pubitemid 26251211)
38. Storz P and Toker A. 3′-Phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. Front Biosci 7: d886-902, 2002.
39. Stoica A, Saceda M, Fakhro A, Joyner M and Martin MB: Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J Cell Biochem 76: 605-614, 2000. (Pubitemid 30083143)
40. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB and Stoica A: Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22: 7998-8011, 2003. (Pubitemid 37175864)
41. Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW and Lin YC: Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Anticancer Res 26: 1773-1784, 2006. (Pubitemid 43989431)
42. Schiff R, Massarweh S, Shou J and Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9: 447S-454S, 2003. (Pubitemid 36105786)
43. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 4: 327-332, 1993.
44. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993. (Pubitemid 23259742)
45. Scotti ML, Langenheim JF, Tomblyn S, Springs AE and Chen WY: Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat 111: 241-250, 2008.
46. Maiello MR, D'Alessio A, De Luca A, Carotenuto A, Rachiglio AM, Napolitano M, Cito L, Guzzo A and Normanno N: AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat 102: 275-282, 2007. (Pubitemid 46474845)
47. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935, 2004. (Pubitemid 38868139)
48. Yoo YA, Kim YH, Kim JS and Seo JH: The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer. Biochim Biophys Acta 1783: 438-447, 2008.
49. Dubska L, Andera L and Sheard MA: HER2 signaling down-regulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS Lett 579: 4149-4158, 2005. (Pubitemid 41021805)
50. Dubska L, Andera L and Sheard MA: HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS Lett 579: 4149-4158, 2005. (Pubitemid 41021805)
51. Kandasamy K and Srivastava RK: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 62: 4929-4937, 2002. (Pubitemid 34984416)
52. Park SY and Seol DW: Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 295: 515-518, 2002.